- Home
- SXTP vs SCNI Comparison
SXTP vs SCNI Comparison
Compare SXTP & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SXTP | SCNI |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 2.6M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | SXTP | SCNI |
|---|---|---|
| Price | $1.99 | $0.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $17.60 | N/A |
| AVG Volume (30 Days) | ★ 155.3K | 34.8K |
| Earning Date | 11-13-2025 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | ★ $1,364,945.00 | $1,147,000.00 |
| Revenue This Year | $146.28 | N/A |
| Revenue Next Year | $24.61 | N/A |
| P/E Ratio | ★ N/A | $3.28 |
| Revenue Growth | 202.10 | ★ 303.87 |
| 52 Week Low | $1.36 | $0.61 |
| 52 Week High | $24.00 | $6.18 |
Technical Indicators
Market Signals| Indicator | SXTP | SCNI |
|---|---|---|
| Relative Strength Index (RSI) | 82.44 | 48.47 |
| Support Level | $0.34 | $0.78 |
| Resistance Level | $2.38 | $0.96 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.17 | 0.02 |
| Stochastic Oscillator | 79.43 | 56.47 |
Price Performance
Historical ComparisonAbout SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.